SLC5A2 and metabolic dysfunction-associated steatotic liver disease: GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis.